{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:09:27Z","timestamp":1771391367803,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,17]]},"DOI":"10.7759\/cureus.103800","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T03:32:33Z","timestamp":1771385553000},"source":"Crossref","is-referenced-by-count":0,"title":["Mycophenolate Mofetil for Induction and as a Steroid-Sparing Agent in the Treatment of Idiopathic Inflammatory Myositis: An Open-Label Study"],"prefix":"10.7759","author":[{"given":"Mariraj","family":"Indiran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathima","family":"Nilofar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashvath","family":"Sarathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Acshay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Daryl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015, 372:1734-47. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg IE","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al.. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021, 7:86. 10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller FW","year":"2018","unstructured":"Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018, 14:255-68. 10.1038\/nrrheum.2018.48","journal-title":"Nat Rev Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie I","year":"2002","unstructured":"Marie I, Hachulla E, Ch\u00e9rin P, et al.. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002, 47:614-22. 10.1002\/art.10794","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105932","article-title":"Treatment of idiopathic inflammatory myopathies","volume":"92","author":"Campanilho-Marques R","year":"2025","unstructured":"Campanilho-Marques R, Fonseca JE, Machado PM. Treatment of idiopathic inflammatory myopathies. Joint Bone Spine. 2025, 92:105932. 10.1016\/j.jbspin.2025.105932","journal-title":"Joint Bone Spine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for myositis","volume":"4","author":"Barsotti S","year":"2018","unstructured":"Barsotti S, Lundberg IE. Current treatment for myositis. Curr Treatm Opt Rheumatol. 2018, 4:299-315. 10.1007\/s40674-018-0106-2","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke H","year":"2002","unstructured":"Sch\u00e4cke H, D\u00f6cke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002, 96:23-43. 10.1016\/s0163-7258(02)00297-8","journal-title":"Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis JR","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J, et al.. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006, 55:420-6. 10.1002\/art.21984","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein RS","year":"2011","unstructured":"Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011, 365:62-70. 10.1056\/NEJMcp1012926","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy","volume":"44","author":"Majithia V","year":"2005","unstructured":"Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005, 44:386-9. 10.1093\/rheumatology\/keh499","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-018-0035-7","article-title":"Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series","volume":"58","author":"Olivo Pallo PA","year":"2018","unstructured":"Olivo Pallo PA, de Souza FH, Miossi R, Shinjo SK. Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series. Adv Rheumatol. 2018, 58:34. 10.1186\/s42358-018-0035-7","journal-title":"Adv Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05590-1","article-title":"Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort","volume":"40","author":"Nair AM","year":"2021","unstructured":"Nair AM, Mathew J, Goel R, et al.. Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clin Rheumatol. 2021, 40:2805-19. 10.1007\/s10067-021-05590-1","journal-title":"Clin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.116232","article-title":"How to calculate sample size for different study designs in medical research?","volume":"35","author":"Charan J","year":"2013","unstructured":"Charan J, Biswas T. How to calculate sample size for different study designs in medical research?. Indian J Psychol Med. 2013, 35:121-6. 10.4103\/0253-7176.116232","journal-title":"Indian J Psychol Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.10.014","article-title":"Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis","volume":"51","author":"Gupta L","year":"2021","unstructured":"Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum. 2021, 51:113-20. 10.1016\/j.semarthrit.2020.10.014","journal-title":"Semin Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider LG","year":"2010","unstructured":"Rider LG, Koziol D, Giannini EH, et al.. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010, 62:465-72. 10.1002\/acr.20035","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S23315","article-title":"Recent treatments of interstitial lung disease with systemic sclerosis","volume":"9","author":"Yasuoka H","year":"2015","unstructured":"Yasuoka H. Recent treatments of interstitial lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med. 2015, 9:97-110. 10.4137\/CCRPM.S23315","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4294-9","article-title":"Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy","volume":"38","author":"Hanaoka H","year":"2019","unstructured":"Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy. Clin Rheumatol. 2019, 38:585-90. 10.1007\/s10067-018-4294-9","journal-title":"Clin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03310-z","article-title":"Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies","volume":"26","author":"Campochiaro C","year":"2024","unstructured":"Campochiaro C, Farina N, De Luca G, et al.. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies. Arthritis Res Ther. 2024, 26:79. 10.1186\/s13075-024-03310-z","journal-title":"Arthritis Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2021.2001331","article-title":"The emerging role of mycophenolate mofetil in interstitial lung diseases","volume":"15","author":"Brown KK","year":"2021","unstructured":"Brown KK, Rajan SK, Shenoy P, Mehta M, Lopez M, Hegde RS, Gogtay J. The emerging role of mycophenolate mofetil in interstitial lung diseases. Expert Rev Respir Med. 2021, 15:1539-49. 10.1080\/17476348.2021.2001331","journal-title":"Expert Rev Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-8-8","article-title":"Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review","volume":"10","author":"Cassone G","year":"2021","unstructured":"Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context. 2021, 10:10.7573\/dic.2020-8-8","journal-title":"Drugs Context"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge JC","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006, 142:65-9. 10.1001\/archderm.142.1.65","journal-title":"Arch Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448103-mycophenolate-mofetil-for-induction-and-as-a-steroid-sparing-agent-in-the-treatment-of-idiopathic-inflammatory-myositis-an-open-label-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T03:32:48Z","timestamp":1771385568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448103-mycophenolate-mofetil-for-induction-and-as-a-steroid-sparing-agent-in-the-treatment-of-idiopathic-inflammatory-myositis-an-open-label-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.103800","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}